Immutep Limited is a biotechnology company based in Sydney, Australia that researches and develops pharmaceutical product candidates for treating cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha, which is currently in Phase IIb clinical trial for treating metastatic breast cancer. The company is also developing other products for the treatment of solid tumors, head and neck squamous cell carcinoma, and non-small cell lung cancer.